- cafead Jul 14, 2021 at 11:02: PM
via In its second enforcement letter of 2021, the US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) flagged issues with Amgen’s promotion of its biological product Neulasta (pegfilgrastim) in a banner ad intended for healthcare professionals.
article source
article source